Physician profile
Muneeb Choudry
NPI 1518924323
$1,194.90
in general payments reported to CMS, 2019-2025
20 companies · $393 in 2025
The $393 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2021: $102 · 2023: $291 · 2024: $176 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $145.10 | 2023 | Lunsumio |
| Karyopharm Therapeutics INC. | $120.86 | 2023 | Xpovio |
| Tempus Ai, INC | $107.54 | 2024-2025 | Xt Cdx |
| Janssen Pharmaceuticals, INC | $100.39 | 2019 | |
| Alexion Pharmaceuticals, INC. | $99.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $96.14 | 2024-2025 | Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $75.00 | 2021 | |
| Daiichi Sankyo INC. | $73.81 | 2023-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $52.32 | 2025 | Opdualag |
| Janssen Biotech, INC. | $49.51 | 2025 | Erleada |
| Pfizer INC. | $44.79 | 2025 | |
| Genzyme Corporation | $39.70 | 2024 | |
| Merck Sharp & Dohme LLC | $32.84 | 2019-2021 | |
| Beone Medicines USA, INC. | $31.34 | 2025 | Brukinsa |
| Lilly USA, LLC | $25.64 | 2025 | Verzenio, Jaypirca |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $24.92 | 2024 | Yescarta |
| Coherus Oncology, INC. | $24.82 | 2025 | Udenyca, Loqtorzi |
| Puma Biotechnology, INC. | $23.25 | 2025 | |
| Emd Serono, INC. | $15.12 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muneeb Choudry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.